Program on Adjuvants and Allergen
Vaccines
Program at a glance
Program at a glance
(*) Optional Course: The Allergome Platform, a course
for Molecular Allergologists Program
Day by Day
Sunday afternoon, May 6th
Plenary Opening
Time |
Activity |
|---|---|
17:00-17:20 |
Welcome. Alexis Labrada, Cuba |
17:20-18:00 |
KNA 1. Asthma, a syndrome of multiple phenotypes and co-morbidities. Richard Lockey, USA |
18:00-18:40 |
KNA 2. Shooting to some immunological paradigms using potent adjuvants. Oliver Pérez, Cuba |
Monday morning,
May 7th
Vigia room: Plenary Session: Novel
approaches for allergen vaccines and allergy immunotherapy
Chairs: Fernández-Caldas E and Valent
Time |
Activity |
|---|---|
09:00-09:20 |
From
mechanisms of allergen-specific immunotherapy towards side
effect-free allergy vaccines. Rudolph Valenta, Austria |
09:25-09:45 |
Development of immunogenic
hypo-allergens for SIT. Fatima Ferreira, Austria |
09:50-10:10 |
New strategies to characterize
allergoids: an old problem revisited. Enrique Fernández
Caldas, Spain |
10:15-10:35 |
Molecular and immunological
characterization of BM32, a grass pollen allergy vaccine
based on non-allergenic peptides fused to hepatitis PreS.
Margarete Focke Tejkl, Austria |
| 10:40-11:00 | Coffee
break |
Chairs:
van Ree R and Larché M |
|
11:00-11:20 |
The
FAST project: Recombinant hypoallergenic approaches for
the treatment of food allergy. Ronald van Ree, The
Netherlands |
11:25-11:45 |
Pet
allergens and new vaccines. Marianne van Hage, Sweden |
11:50-12:10 |
Peptide
immunotherapy. Mark Larché, Canada |
12:15-12:35 |
Clinical
efficacy of cat-ToleroMune peptide immunoterapy. Results
from a phase IIB clinical trial. Rod Hafner, UK |
Monday
afternoon, May 7th
Vigia room 1: Allergen structure
and function
Chairs: Chapman M and Mari
A
Time |
Activity |
|---|---|
14:00-14:20 |
Biochemical,
immunological, and clinical features of allergenic molecules:
do they always overlap? Adriano Mari, Italy |
14:25-14:45 |
Immunoassay based methods
for allergen analysis Martin Chapman, USA |
14:50-15:10 |
Structural biology of
allergens and allergen/antibody complexes. Anna
Pomés, USA |
15:15-15:25 |
SOP.
A novel Device for the detection of surface deposited
dust mite allergens. A simple sampling, dilution and analysis
technique. Eduardo Egea, Colombia |
| 15:30-15:45 | Coffee
break |
Chairs:
Himly M and Briza P |
|
15:45-16:05 |
Lessons
from recombinant allergens and hypoallergenic variants
on protein aggregation allergenicity and immunogenicity.
Martin Himly, Austria |
16:10-16:30 |
Mass
spectrometry and proteomics in allergen characterization.
Peter Briza, Austria |
16:35-16:55 |
Food
allergens, lessons from the Ber e 1 model system. Marcos
Alcocer, UK |
16:55-17:05 |
SOP.
Effect of boiling on aggregate formation and on the allergenicity
of Ara h 1 and Ara h 2/6 from peanut. Yvonne Vissers,
Switzerland |
Vigia room 1: Optional Course Part I
| Time | Activity |
|---|---|
17:30-18:30 |
The
Allergome Platform, a course for Molecular Allergologists.
Adriano Mari, Italy |
Monday
afternoon, May 7th
Vigia room 2: New
Generation of Adjuvants
Chairs: Fresno M and Batista
A
Time |
Activity |
|---|---|
14:00-14:30 |
KNA
3: Toll-like receptors
based adjuvants: towards specific induction of protective
immune responses. Manuel Fresno, Spain |
14:35-14:55 |
Effects of different adjuvant
formulations on cellular migration, maturation and antigen
trafficking from the site of vaccination. Els N
Meeusen, Australia |
15:00-15:20 |
Combination adjuvants
signaling through TLR9. Thorunn Olafsdottir, Sweden |
| 15:25-15:40 | Coffee
break |
15:40-16:00 |
VLP as adjuvants. Gerardo
Guillén, Cuba |
16:05-16:25 |
Liposomes as immunoadjuvants:
Contribution of B-1 cells and immunopotentation with encapsulation
of Sticholysins, pore-forming proteins of the sea anemone
Stichodactyla helianthus. María E Lanio, Cuba |
16:30-16:50 |
Saponins
from Quillaja brasiliensis form ISCOM-like particles. Fernando
Ferreira, Uruguay |
16:55-17:15 |
Anchor
characteristics of artificially membrane anchored cytokines
applied as 'natural adjuvants' bound to Virus-like particles
are key to their optimal biological function. Daniela
Wojta-Stremayr, Austria |
17:20-17:40 |
New
developments using probiotic spores as alive adyuvants in
vaccines. Roberto Grau, Argentina |
17:45-18:05 |
Understanding
adjuvant immunotoxicity mechanisms for improve the safety
evaluation during vaccine development. Alexander
Batista, Cuba |
Tuesday
morning, May 8th
Vigia room: Plenary Session: Adjuvants
to Allergy Vaccines
Chairs: Russo M and Moingeon
P
Time |
Activity |
|---|---|
09:00-09:20 |
Toll-like
receptors in allergy. Momtchilo Russo, Brazil |
09:25-09:45 |
Adjuvants and vector systems
for the sublingual route. Phillip Moingeon, France |
09:50-10:10 |
Preclinical development
of TLR-ligand allergen fusion proteins as allergen vaccines.
Stephan Scheurer, Germany |
10:15-10:35 |
Clinical trials with TLR
ligands for treatment of asthma and allergic diseases. Peter
Creticos, USA |
10:40-11:00 |
Coffee
break |
| 11:00-11:20 |
MPL® as an adjuvant in
allergy vaccines. Tom Holdich, UK |
| 11:25-11:45 |
Proteo-Cochleate
adjuvant platform for allergic vaccines. Oliver
Pérez, Cuba |
11:50-12:05 |
SOP.
IgG/IgE shift and Th1 response induced by a Dermatophagoides
siboney vaccine using the AFPL1® combination adjuvant in
sensitized mice. Wendy Ramírez, Cuba |
12:10-12:25 |
SOP.
Immunomodulatory antiallergic effect of a nano-liposome
formulation containing Dermatophagoides siboney allergens
and TLR ligands by sublingual route. Beatriz Tamargo,
Cuba |
Tuesday
afternoon, May 8th
Vigia room: Plenary Debate: Dose-response
Relationship in Allergy and Cancer Immunotherapy
Chairs: Lockey R and Fernández
LE
Time |
Activity |
|---|---|
14:00-14:15 |
Dose-response
effect in allergen IT (Task Force Paper EAACI). Desirée
Larenas, Mexico |
14:15-14:30 |
Clinical proof of concept
for SQ-standardised house dust mite allergy immunotherapy
tablets in patients with respiratory allergy. Jorgen
Larsen, Denmark |
14:30-14:45 |
Defining the optimal biological
dose: The NGcGM3/VSSP cancer vaccine, a case study. Luis
E Fernández,Cuba |
14:45-15:05 |
General Discussion |
Vigia room: Plenary Session: WAO-AAAAI special seminar on subcutaneous immunotherapy
Time |
Activity |
|---|---|
| 15:10-15:40 |
Allergen
Immunotherapy, A 2011 Practice Parameter Update. Richard
Lockey, USA |
15:40:16:10 |
Allergen Immunotherapy,
Prevention, Recognition and Treatment of Systemic Allergic
Reactions. Dennis Ledford, USA |
16:10-16:30 |
Discussion |
Vigia room: Plenary Poster Session and Rum Testing
Session: 16:30-19:00
Wednesday
morning, May 9th
Vigia room: Plenary Session: Immunobiology
of Allergy
Chairs: Crameri R and Rhyner
C
Time |
Activity |
|---|---|
| 09:00-09:20 |
The diagnosis is the first step of any allergen specific immunotherapy: are we measuring what we should? Reto Crameri, Switzerland |
09:25-09:45 |
IgE-binding epitopes: facts and speculations. Claudio Rhyner, Switzerland |
| 09:50-10:10 |
Allergen-specific CD4+ T cell responses in healthy, allergic individuals and during immunotherapy. Phillip Moingeon, France |
10:15-10:35 |
Immunosomes for modulation
of allergen-specific immune responses. Winfried
Pickl, Austria |
| 10:40-11:00 |
Coffee
break |
| Chairs: Platts-Mills T and Caraballo L | |
| 11:00-11:20 |
Parasite infections and
allergen sensitization. Luis Caraballo, Colombia |
11:25-11:45 |
The
effect of single and multiple infections in atopy and wheezing
in Latin American children. Neuza Alcantara Neves,
Brazil |
11:50-12:10 |
The
role of fattic acid binding proteins in allergy. Leonardo
Puerta, Colombia |
12:15-12:35 |
Neural
pathways in allergy. Luciana Mirotti, Brazil |
Wednesday
afternoon, May 9th
Vigia room 1: Pharmaceutical
and pharmacological development of allergen vaccines
Chairs: Barber D and Dreborg
D
Time |
Activity |
|---|---|
| 14:00-14:20 |
Bioavaliability
of allergen vaccines. Domingo Barber, Spain |
14:25-14:45 |
Safety
aspects of allergen subunit vaccines. Erika Jensen-Jarolim,
Austria |
14:50-15:10 |
Pharmacokinetics
and standardization of mPEG modified allergens. Sten
Dreborg, Sweden |
15:15-15:35 |
Using
mass spectrometry for determination of major allergens in
allergen standardization. Ulla Seppala, Denmark |
| 15:40-15:55 |
Coffee
break |
| Chairs: Kerkvliet E and Neubauer A | |
| 15:55-16:15 |
Potency
tests for modified and alum-adsorbed modified products.
Erica Kerkvliet, The Netherlands |
16:20-16:40 |
Quality
and allergen composition of mite allergen source materials.
Betty Goedewaagen, The Netherlands |
16:45-17:05 |
Development of BM32 -
a Recombinant Vaccine for Immunotherapy of Grass Pollen Allergy: from R&D to First
Clinical Trials. Angela Neubauer, Austria |
17:10-17:30 |
GMP
manufacturing and quality control of recombinant allergy
vaccines. Hans Huber, Austria |
Vigia room 1: Optional Course Part II
| Time | Activity |
|---|---|
| 17:50-18:50 |
The
Allergome Platform, a course for Molecular Allergologists.
Adriano Mari, Italy |
Wednesday
afternoon, May 9th
Vigia room 2: Adjuvants
for infectious diseases vaccines
Chairs: Guzman MG and Romeu
B
Time |
Activity |
|---|---|
14:00-14:20 |
Advances
of Cuban dengue vaccine candidates. Adjuvant uses. María
G Guzman, Cuba |
14:25-14:45 |
Virus
like particles based on the recombinant capsid protein of
dengue-2 enhance the immune response against recombinant
proteins. Ernesto Marcos, Cuba |
14:50-15:10 |
Recombinant
H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide
adjuvant: Randomized clinical trial of immunogenicity and
safety. Jeffrey J Bowden, Australia |
15:15-15:35 |
AFCo1
and AFPL® overcome the thymus-independent stimuli of unconjugated
polysaccharide antigens. Belkis Romeu, Cuba |
| 15:40-15:55 |
Coffee
break |
Vigia room
2: Adjuvants to chronic
infectious and non-infectious diseases
Chairs: Christensen D and
Acosta A
Time |
Activity |
|---|---|
| 15:55-16:15 |
On
the role of vaccine delivery for the induction of functional
immuneresponses by TB vaccines. Dennis Christensen,
Denmark |
16:20-16:40 |
Adjuvants
modulate the immune response to proteoliposomes of Micobaterium
smegmatis in mice. Armando Acosta, Cuba |
16:45-17:05 |
DNA
vaccines for the prophylaxis of tuberculosis. Marta
Romano, Belgium |
17:10-17:30 |
Mimotope
vaccines in cancer to induce IgG or IgE. Erika Jensen-Jarolim,
Austria |
17:35-17:55 |
Towards
an Adjuvant for Immunocompromised Scenarios. Luis
E Fernández, Cuba |
| 18:00-18:10 |
SOP.
Co-administration of CR3 with core and surface hepatitis
B antigens induces a Th2-Th1 shift of the HIV-specific response.
Darien García, Cuba |
Thursday
morning, May 10th
Vigia room 1: Regulatory
outlook, allergen immunotherapy and Allergy Care
Chairs: Rabin R and Fernández
L
Time |
Activity |
|---|---|
09:00-09:20 |
Status
of allergen products in USA. Ronald Rabin, USA |
09:25-09:45 |
Product
regulation approach and batch release in Germany. Detlef
Bartel, Germany |
09:50-10:10 |
Current
situation of allergenic extracts registration in Brazil.
Victor Cunha, Brazil |
| 10:15-10:35 |
Progress
in regulation of therapeutic vaccines and biological products
in Cuba. Judith Cartaya, Cuba |
| 10:40-11:00 |
Coffee
break |
| Chairs: Fernández Caldas E and Labrada A | |
| 11:00-11:20 |
Design
of novel sublingual and subcutaneous immunotherapies in
Latin American countries. Jorge F Maspero, Argentina |
11:25-11:45 |
Introducing
allergen immunotherapy into the public healthcare sector:
the Cuban experience. Alexis Labrada, Cuba |
11:50-12:10 |
Management
of occupational allergy. Miguel Hinojosa, Spain |
12:15-12:35 |
Round
Table Discussion. The impact of allergic conditions on children
with speech and language disorders. Ruth Creticos,
USA |
Vigia room
2: Adjuvants for veterinary
vaccines
Chairs: Ascarateil S and
Sifontes S
Time |
Activity |
|---|---|
09:00-09:30 |
KNA
4. Vaccine adjuvants designed for veterinary
and human use. Stephane Ascarateil, France |
09:35-09:55 |
Use
of efficiency model in the Aquiculture experimentation.
Domingo W. Fonticiella, Cuba |
10:00-10.20 |
Fish
diseases and use of vaccines, probiotics and other pharmaceutical
products in aquaculture. Domingo W. Fonticiella,
Cuba |
10:25-10:45 |
Immunochemotherapy
using nitrovynilfuran compounds entrapped in immunoactive
cochleate structures. Sergio Sifontes, Cuba |
| 10:50-11:05 |
Coffee
break |
11:05-11:25 |
Methodology
to design and optimize stable oily formulations using Montanide
888 VG. Carlos E Pérez, Cuba |
11:05-11:25 |
SOP.
Adjuvant use in production of tetanous antitoxin in horses.
Antonio Miranda, Cuba |
12:45-11:55 |
SOP.
Obtainment of aqueous and oily vaccines against paramyxovirus
type 1 infection in pigeons and assessment of immune response.
Syduet, González, Cuba |
12:00-12:10 |
SOP.
Comparison of the adjuvant activity of aluminum hydroxide
and calcium phosphate on the antibody response towards the
Bothrops asper snake venom. Mauren Villalta-Arrieta,
Costa Rica |
Thursday
afternoon, May 10th
Vigia room 1: Clinical
Trials of Allergen Immunotherapy
Chairs: Creticos P and Larsen
J
Time |
Activity |
|---|---|
14:00-14:20 |
Primary
endpoints, validation, and clinical efficacy in trials with
subcutaneous and sublingual immunotherapy. Peter
Creticos, USA |
14:25-14:45 |
Disease
modifying effect of a SQ-standardised grass pollen allergy
immunotherapy tablet. Jorgen Larsen, Denmark |
14:50-15:10 |
Recombinant
allergens for allergen specific immunotherapy. Andreas
Nandy, Germany |
15:15-15:35 |
Hypoallergenic
Bet v 1 derived contiguous overlapping peptides are well
tolerated in human and lead to sustained immunological responses.
Reymond C, Switzerland |
| 15:40-15:55 |
Coffee
break |
Vigia room: Plenary Closure
Time |
Activity |
|---|---|
| 16:00-16:30 |
KNA 5. IgE antibody responses:
understanding the interaction between adjuvants and route
of exposure. Thomas Platts-Mills, USA |
| 16:35 | Closing remarks. Belkis
Romeu, Alexis Labrada, and Oliver Pérez, Cuba |
Posters
Session
I. Adjuvants
No. |
Poster |
|---|---|
1 |
Role
of B-1 cells in the immune response against an antigen
encapsulated into phosphatidylcholine-containing liposomes.
Y Cruz-Leal, Cuba |
2 |
Liposomes
encapsulating Sticholysins with immunoadjuvant properties
to stimulate an antigen-specific cellular immune response.
RJ Laborde, Cuba |
3 |
Aluminum
phosphate as adjuvant improves the immunogenicity of monovalent
conjugates against serotypes 1, 14 and 19F of Streptococcus
pneumoniae. A Pérez, Cuba |
4 |
Synthesis and evaluation
of fresh aluminum phosphate for its possible use as adjuvant.
L Nadal, Cuba |
5 |
Comparison of freshly
prepared aluminum phosphate and commercial Adju-phos adsorption
capacity. Y Serrano, Cuba |
6 |
The hen’s egg test on
chorioallantoic membrane (HET-CAM), useful in vitro assay
for assessing irritation properties of immunoadjuvants
formulations. A Batista-Duharte, Cuba |
7 |
Molecular mimicry between
mayor proteins from Neisseria meningitidis B and self-proteins
is insufficient condition for triggering early post-vaccination
autoimmunity in mice and rats vaccinated with OVM-derived
adjuvants. A Batista-Duharte, Cuba |
| 8 |
Obtain
of aqueous and oily vaccines against Paramyxovirus Type
1 infection in pigeons and assessment of immune response.
S González, Cuba |
9 |
A Recombinant Vaccine of H5N1 HA1 Fused with Foldon and
Human IgG Fc Induced Complete Cross-Clade Protection against
Divergent H5N1 Viruses. BJ Zheng, China |
10 |
Adjuvant
effect of bacterial outer membrane vesicles with penta-acylated
lipopolysaccharide on antigen-specific T cell priming.
DH Lee, Korea |
11 |
Preliminary results of AFCo1 and AFPL1 co-administered
with rPhl p5 by parenteral and mucosal route in mouse,
M Cuello, Cuba |
12 |
Diverse
adjuvant activity of saponins from the South American
flora. F Silveira, Uruguay |
13 |
Comparison
of the adjuvant activity of aluminum hydroxide and calcium
phosphate on the antibody response towards the Bothrops
asper snake venom. M Villalta, Costa Rica |
14 |
Co-administration
of CR3 with core and surface hepatitis B antigens induces
a Th2-Th1 shift of the HIV-specific response. D
García, Cuba |
15 |
IMS4112
and VLP of HBV as adjuvants for a quimeric protein of
HIV-1. I Rodriguez-Alonso, Cuba |
16 |
Influence
of the adjuvant in the immune response to proteoliposomes
and liposomes from non-pathogenic mycobacteria in mice.
ME Sarmiento, Cuba |
17 |
Comparison
of the adjuvanticity of different oil/water emulsions
prepared with Freund´s adjuvant on the antibody response
towards snake venoms. K Rodríguez, Costa Rica |
18 |
Very
small size proteoliposomes derived from Neisseria meningitidis:
an effective adjuvant for antigen-specific cytotoxic T
lymphocyte response stimulation under leukopenic conditions.
L Oliver, Cuba |
19 |
Results
of repeated dose intramuscular administration of the adjuvant
combination Montanide ISA51 VG/VSSP in Sprague Dawley
rats. A. Mancebo, Cuba |
20 |
Interleukin
2 mutein as adjuvant for anticancer therapies. JA
Sánchez, Cuba |
21 |
From
Neisseria meningitidis serogroup B vaccine to Potent Adjuvants.
M Lastre, Cuba |
22 |
Physicochemical and Biological Characterization of 1E10
Idiotypic Vaccine. Y. Machado, Cuba |
23 |
Consistency
of the manufacturing process for active pharmaceutical
ingredients for gangliosides vaccines (NGcGM3/VSSP and
NAcGM3/VSSP) in BioCen. M Alvarez, Cuba |
24 |
Influence
of phosphate salts and alum content on to the immunogenicity
of a Dermatophagoides siboney AFPL1-adjuvanted vaccine.
R Samalea, Cuba |
II. Novel Allergy Vaccines and Pharmacological Preclinical Evaluation
No. |
Poster |
|---|---|
25 |
Usefulness
of a murine model of respiratory challenge test for
the preclinical pharmacological evaluation of novel
allergen vaccines. V Bourg, Cuba |
26 |
Experimental
model of asthma to Blomia tropicalis recombinant antigens.
NM Alcântara Neves, Brazil |
27 |
Potential
of Brazilian Natural Products as immunomodulators of
allergic diseases. CA Figueiredo, Brazil |
28 |
Effects
of 4-Alil-2-Metoxifenol in murine model of allergic
respiratory disease induced by Blomia tropicalis mite.
CA Figueiredo, Brazil |
29 |
Toxicity
assay in repeated doses of Dermatophagoides siboney
allergen extract in mice. Y González, Cuba |
30 |
Enzymatic
activity in native and polymerized mite allergen extracts.
JI Tudela, Spain |
31 |
Beneficial
Effect of Hydrolyzed Egg in Allergy. YM Vissers,
Switzerland |
32 |
Histological analysis as a tool for the preclinical
pharmacological evaluation of therapeutic allergy vaccines.
JF Infante Bourzac, Cuba |
33 |
Dose
repeat toxicity and local tolerance of a novel nano-liposome
adjuvanted allergen vaccine. A Morejón, Cuba |
III. Allergen Immunotherapy, Clinical Trials and Clinical Practice
No. |
Poster |
|---|---|
34 |
Clinical
evolution of allergic patients under immunotherapy
with Valergen.mite vaccines. AO Benítez Goitizolo,
Cuba |
35 |
Adherence
and tolerability of mite allergen sublingual immunotherapy
with different dosing schedules in asthmatic children.
R Castro Almarales, Cuba |
36 |
Efficacy
and Safety of a Novel Ragweed Allergy Immunotherapy
Tablet (AIT) During Peak Season in North America.
P Creticos, USA |
37 |
Adverse
Events related to allergen immunotherapy with standardized
House Dust Mite vaccines in asthmatic patients. AO
del Arco Pérez, Cuba |
38 |
Effectiveness
and impact on Quality of Life of Sublinual Inmunotherapy
with House Dust Mite vaccines in allergic conjunctivitis.
I Figueroa García, Cuba |
39 |
Adverse
reactions to allergen immunotherapy using house dust
mite vaccines in asthmatic patients. Y Fuentes
Páez, Cuba |
40 |
Clinical
response to subcutaneous immunotherapy (SIT) in polysenzitised
profiline positive patients is reflected by the modification
of allergen-specific IgE, IgG4, IgE/IgG4- Ratio levels
measured by Microarray technique (ISAC 112). Gay-Crosier
F, Switzerland |
41 |
3-years
course of allergen-specific immunotherapy (ASIT) in
children with allergic diseases. A Gevorkyan,
Russia |
42 |
Immunologic
and clinical efficacy of sublingual immunotherapy
with House Dust Mite allergen vaccines in pediatric
patients with persistent moderate allergic rhinitis.
JV González Abreu, Cuba |
43 |
Allergy
Training and Immunotherapy in Latin America: How Survey-results
lead to a Regional Overview. D Larenas-Linnemann,
Mexico |
44 |
Cycloferon
enhances the effectiveness of SCIT. L Lazarenko,
Russia |
45 |
Preliminary
results of a national pharmacovigilance study of allergen
injection and sublingual immunotherapy with house
dust mite allergen extracts. M Mateo Morejón,
Cuba |
46 |
Efficacy
and safety of immunotherapy with Valergens Dp and
Bt extracts in asthmatic adults. M Morales
Irarragorri, Cuba |
47 |
Sublingual
Immunotherapy and Quality of Life in asthmatic patients.
R Naranjo Robalino, Cuba |
48 |
Assessment
of efficacy and safety of allergen immunotherapy with
standardized mite allergen vaccines in the clinical
practice. TC Pérez Jiménez, Cuba |
49 |
A
Report of Pharmacovigilance of Adverse Reactions to
Allergen Immunotherapy by Sublingual Route in asthmatic
patients. VR Pérez Rodríguez, Cuba |
50 |
Safety
of Sublingual Immunotherapy with Standardized Vaccines
of Domestic Mites. M Ronquillo Díaz, Cuba |
51 |
Adverse
reactions to subcutaneous allergen immunotherapy in
patients with asthma, rhinitis and /or atopic dermatitis
with an ultra rush buildup immunotherapy. J
Sánchez, Colombia |
52 |
Elevated tear fluid levels of MIP-1 alfa in patients
with atopic dermatitis. M Mrugacz, Poland |
IV. Allergen Characterization, Allergen-Specific Diagnostics, Cross reactivity and Exposure
No. |
Poster |
|---|---|
53 |
Allergic
sensitization and IgE binding profile to hen’s egg
allergens in Cuban adults and children. D
Álvarez Díaz, Cuba |
54 |
Sensitization
to storage mites, wheat and yeast allergens in Cuban
bakers. M Álvarez-Castello, Cuba |
55 |
Cross-reactivity
between Olea europaea and Betula verrucosa extracts.
B Cases, Spain |
56 |
Allergic
sensitization and IgE/IgG4 profile to Soy food and
respiratory allergens in Cuban adults and children.
R Cruz Jiménez, Cuba |
57 |
Sensitization
to mite allergens and its role in atopic dermatitis
in children. A Díaz Rodríguez, Cuba |
58 |
Serodiagnosis
of allergy to Blomia tropicalis using recombinant
antigens instead of whole mite extract increases the
assay specificity. JCM Ponte, Brazil. |
59 |
IgY
Policlonal antibodies Conjugated to Colloidal Gold
Nanoparticles as a novel tool for the detection of
of Dust Mite Allergens. E Egea, Colombia |
60 |
A
novel Device for the detection of surface deposited
dust mite allergens. A simple sampling, dilution and
analysis technique. E Egea, Colombia |
61 |
House
Dust Mite Fauna and its Relationship to Allergen Skin
Tests in Six Mexican States. BI Fernández
Duro, Cuba |
| 62 |
Sensitization
to Dermatophagoides pteronyssinus, Dermatophagoides
siboney and Blomia tropicalis in children from three
family physician’s offices. M González León,
Cuba |
63 |
Allergic
sensitization and IgE/IgG4 profile to wheat food allergens
in Cuban adults and children. M Jiménez, Cuba |
64 |
n
silico dimerization propensity study of house dust
mite allergens from families 5 and 21. S Khemili,
Algeria |
65 |
Allergen
sensitization patterns in Mexican patient with rhinitis
symptoms: a prospective nation-wide study. D
Larenas Linnemann, México |
66 |
Sensitization
to three domestic mites in allergic children in a
suburban area in Cuba. MC Reyes Zamora, Cuba |
67 |
Is
sensitisation to Cupressus spp. (Cypress) and Platanus
spp. due to allergen exposure or cross-reactivity?
J Subiza, Spain |
68 |
Is
allergy to peanut important in Cuba? D Torralba
Averoff, Cuba |
69 |
Blo
t 12 as a species-specific marker of Blomia tropicalis.
J Zakzuk, Colombia |
V. Epidemiology of asthma and allergic diseases. Allergy and parasitism
| No. |
Poster |
|---|---|
70 |
Food
and nutrition insecurity: a marker of vulnerability
to asthma symptoms. NM Alcantara-Neves, Brazil |
71 |
Prevalence
of asthma and its association with body mass index
and abdominal obesity in children from a small Brazilian
town. NM Alcantara-Neves, Brazil |
72 |
Atopy
as a risk factor for recurrent Upper Respiratory Tract
Infections in children under 5 years. A Ciria
Martín, Cuba |
73 |
The
speciific IgE Anti Ascaris lumbricoides seems to influence
the serologic IgE response to Indoor allergens in
Colombian pediatric asthmatic patients. E
Egea, Colombia |
74 |
Sensitisation
to Der p1, Der p2, Der p10, Ascaris suum and shrimp
in a population of allergic patients living on the
tropical Caribbean Island of Martinique. S
Lafosse-Marin, Martinique, France |
75 |
Cross-reactivity
between Dermatophagoides pteronyssinus, Ascaris suum,
Anisakis simplex, shrimp, and two tropomyosins of
different shrimp species in Martinique.S Lafosse-Marin,
Martinique, France |
| 76 |
Association
between asthma and IgE levels. M Martínez,
Venezuela |
| 77 |
Cross-reactivity
between anti-mite and anti-helminth IgE antibodies
and their effect in the diagnosis of atopy by IMMUNOCAP
assay. JCM Ponte, Brazil |
78 |
Identification
of protein fractions obtained from somatic extract
of Toxocara canis with immunoregulatory effects on
peripheral blood mononuclear cells of allergic and
non-allergic donors. NM Alcantara-Neves, Brazil |
79 |
Association
between FeNO and IgE levels in Patients with allergic
asthma. J Torres, Venezuela |
80 |
Longitudinal
study "Natural history of asthma in Havana, Cuba":
results from the first year. SJ Venero-Fernández,
Cuba |
VI. Standardization, Pharmaceutical, Quality and Regulatory Aspects of Allergen Vaccines
No. |
Poster |
|---|---|
81 |
Allergenic
potency of Parietaria judaica and Olea europaea using
different serum pools containing, or not, specific IgE
to the major allergens. E Abel-Fernández, Spain |
82 |
Quality
Risk Management application in the manufacturing process
of raw allergenic material of house dust mite vaccines.
PC Alfonso, Cuba |
83 |
Grass
and mite mixtures: how does the proteolytic activity
of Dermatophagoides pteronyssinus affect Phleum pratense
extracts? E Fernández-Caldas, Spain |
84 |
Process
consistency of Dermatophagoides siboney purified allergen
fraction as the active pharmaceutical ingredient for
a novel adjuvanted allergen vaccine. D Martínez,
Cuba |
85 |
Stability
study of food allergen extracts in glycerin and aqueous
formulation. A Más Quintero, Cuba |
86 |
Stability
study of bulk allergen extracts of House Dust Mites
in freezing state. M Odelin, Cuba |
87 |
A
simple method for assessing Ultrafiltration efficiency
for allergen extracts. O Oliva Díaz, Cuba |
| 88 |
Validation
of sterile filtration processes of house dust mite allergen
vaccines. Y Perea, Cuba |
89 |
Use
of gamma-sterilized rubber stoppers for assuring lower
moisture content in lyophilized house dust mite allergenic
extracts. H Pérez, Cuba |
90 |
Microbial
bioburden during the culture process of Dermatophagoides
pteronyssinus. M Sánchez, Cuba |
91 |
Risk
Analysis applied to Quality Improvement of the manufacturing
process of the Active Pharmaceutical Ingredient of allergen
vaccines. N Seuret Hernández, Cuba |
92 |
Establishing
pharmacopeia a validated sterility test for glycerinated
allergen extracts. A Tsoraeva, Cuba |
93 |
Cuban
National Regulatory Authority: Legal Basis for Allergenic
Products. L Fernández, Cuba |
